(-0.52%) 5 081.00 points
(-0.30%) 38 565 points
(-0.90%) 17 506 points
(0.22%) $82.99
(-1.45%) $1.629
(0.01%) $2 338.70
(0.34%) $27.44
(0.26%) $918.20
(-0.24%) $0.932
(-0.36%) $10.94
(-0.46%) $0.799
(-0.22%) $92.12
@ $40.50
発行日: 9 4月 2024 @ 22:36
リターン: -3.41%
前回のシグナル: 4月 9 - 01:23
前回のシグナル:
リターン: 0.25 %
Live Chart Being Loaded With Signals
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally...
Stats | |
---|---|
本日の出来高 | 597 776 |
平均出来高 | 1.04M |
時価総額 | 4.97B |
EPS | $0 ( 2024-02-20 ) |
次の収益日 | ( $0.690 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 18.63 |
ATR14 | $0.0220 (0.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-17 | Labarre Michael J. | Buy | 10 000 | Common Stock |
2024-04-17 | Labarre Michael J. | Sell | 10 000 | Common Stock |
2024-04-16 | Labarre Michael J. | Sell | 10 000 | Common Stock |
2024-04-16 | Labarre Michael J. | Sell | 10 000 | Option to Purchase Common Stock |
2024-04-17 | Labarre Michael J. | Sell | 10 000 | Option to Purchase Common Stock |
INSIDER POWER |
---|
15.86 |
Last 100 transactions |
Buy: 612 606 | Sell: 449 990 |
ボリューム 相関
Halozyme Therapeutics Inc 相関
10 最も負の相関 | |
---|---|
TLGT | -0.945 |
SVAC | -0.942 |
GOODM | -0.919 |
SIBN | -0.88 |
RPHM | -0.88 |
PAIC | -0.872 |
SNPO | -0.86 |
MTSL | -0.85 |
PYXS | -0.845 |
XOG | -0.843 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Halozyme Therapeutics Inc 相関 - 通貨/商品
Halozyme Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $829.25M |
総利益: | $636.89M (76.80 %) |
EPS: | $2.13 |
Q4 | 2023 |
収益: | $230.04M |
総利益: | $177.74M (77.27 %) |
EPS: | $0.660 |
Q3 | 2023 |
収益: | $216.03M |
総利益: | $161.21M (74.62 %) |
EPS: | $0.620 |
Q2 | 2023 |
収益: | $221.04M |
総利益: | $170.97M (77.35 %) |
EPS: | $0.570 |
Financial Reports:
No articles found.
Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。